Midatech Pharma PLC R&D Programme Focused on Leptomeningeal Disease
27 Março 2023 - 8:46AM
RNS Non-Regulatory
TIDMMTPH
Midatech Pharma PLC
27 March 2023
27 March 2023
Midatech Pharma PLC
("Midatech" or the "Company")
New Preclinical R&D Programme Focused on Leptomeningeal
Disease
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery
technology company focused on improving the bio-delivery and
bio-distribution of medicines, is pleased to announce a new
research programme coded MTD217 focusing on developing new
therapeutic options for metastatic cancers with high unmet
needs.
Background
Many cancers exhibit high levels of metabolic plasticity, i.e.
the ability to switch between energy-generating pathways in
response to cellular stresses[1], such as those caused by
chemotherapy. Highly proliferative cancers frequently use the
aerobic glycolysis pathway, known as "the Warburg effect", to
generate energy(2) . Oxidative Phosphorylation (OXPHOS) is another
critical mechanism that enables a variety of fuel sources to be
used to generate adenosine triphosphate (ATP), a molecule present
in cells that provides energy for metabolic processes. When under
induced stress, cancer cells switch away from aerobic glycolysis
and significantly increase reliance on the alternative OXPHOS
pathway. Inhibiting the OXPHOS pathway represents a potential means
of targeting both primary and metastatic tumour lesions in
patients. OXPHOS can be inhibited by a range of small molecule
therapeutics, however systemic administration of these generally
causes undesirable toxic effects in healthy cells(3) .
MTD217
Midatech's MTD217 programme explores simultaneous inhibition of
key metabolic pathways, including the Warburg effect and OXPHOS.
The research is centred around a number of new water-soluble drug
formulations that can be easily infused or injected simultaneously,
or sequentially, directly into the cancer microenvironment,
disrupting metabolic functions in a highly localised manner, thus
limiting off-target toxicity. The Company has already been able to
demonstrate up to a six-fold synergistic effect of administering
its formulation of panobinostat, known as MTX110, with an OXPHOS
inhibitor in vitro with three patient-derived cells lines. On the
back of those data, Midatech has established new patent positions
to protect these combination formulations.
The Company's initial target is treatment of leptomeningeal
disease, a lethal complication in which metastatic cancer cells
invade the cerebrospinal fluid and central nervous system(4) . In
collaboration with several large academic centres, Midatech is now
accelerating preclinical studies to generate proof of concept data
in this setting that can support a future clinical trial
application.
Dr Dmitry Zamoryakhin, MD, MBA, CSO of Midatech, commented :
" We are very excited about accelerating this promising
programme towards first-in-human studies. It capitalises on
Midatech's knowledge in direct intratumoral delivery of drugs,
currently being explored in our clinical programme of MTX110 in
recurrent glioblastoma. Furthermore, blockage of the OXPHOS pathway
by MTD217 opens opportunities to demonstrate potential synergistic
effects with checkpoint inhibitors in solid tumours as well as
exploration of co-treatment with MTX110 in patients with aggressive
brain tumours. "
[1] Ahmat et.al Tumour microenvironment and metabolic plasticity
in cancer and cancer stem cells: Perspectives on metabolic and
immune regulatory signatures in chemoresistant ovarian cancer stem
cells. Semin Cancer Biol. 2018 Dec; 53:265-281
2 Trang et.al Therapeutic Drug-Induced Metabolic Reprogramming
in Glioblastoma. Cells 2022, 11, 2956
3 Emmings et.al Targeting Mitochondria for Treatment of
Chemoresistant Ovarian Cancer. Int J Mol Sci. 2019;20(1):229.
Published 2019 Jan 8. doi:10.3390/ijms20010229
4 Law et.al A preclinical model of patient-derived cerebrospinal
fluid circulating tumor cells for experimental therapeutics in
leptomeningeal disease from melanoma. Neuro-Oncology 24(10),
1673-1686, 202
For more information, please contact:
Midatech Pharma PLC
Dmitry Zamoryakhin, CSO
Tel: +44 (0)29 20480 180
www.midatechpharma.com
Strand Hanson Limited (Nominated Adviser and Broker)
James Dance / Matthew Chandler / Rob Patrick
Tel: +44 (0)20 7409 3494
IFC Advisory Limited (Financial PR and UK Investor Relations)
Tim Metcalfe / Graham Herring
Tel: +44 (0)20 3934 6630
Email: midatech@investor-focus.co.uk
Edison Group (US Investor Relations)
Alyssa Factor
Tel: +1 (860) 573 9637
Email: afactor@edisongroup.com
Forward-Looking Statements
Certain statements in this announcement may constitute "forward-looking
statements" within the meaning of legislation in the United
Kingdom and/or United States. Any forward-looking statements
are based on currently available competitive, financial and
economic data together with management's views and assumptions
regarding future events and business performance as of the
time the statements are made and are subject to risks and
uncertainties. The Company wishes to caution you that there
are some known and unknown factors that could cause actual
results to differ materially from any future results, performance
or achievements expressed or implied by such forward-looking
statements.
Reference should be made to those documents that the Company
shall file from time to time or announcements that may be
made by the Company in accordance with the London Stock Exchange's
AIM Rules for Companies ("AIM Rules"), the Disclosure and
Transparency Rules ("DTRs") and the rules and regulations
promulgated by the US Securities and Exchange Commission,
which contains and identifies other important factors that
could cause actual results to differ materially from those
contained in any projections or forward-looking statements.
These forward-looking statements speak only as of the date
of this announcement. All subsequent written and oral forward-looking
statements by or concerning the Company are expressly qualified
in their entirety by the cautionary statements above. Except
as may be required under the AIM Rules or the DTRs or by relevant
law in the United Kingdom or the United States, the Company
does not undertake any obligation to publicly update or revise
any forward-looking statements because of new information,
future events or otherwise arising.
About Midatech Pharma PLC
Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ:
MTP) is a drug delivery technology company focused on improving
the bio-delivery and bio-distribution of medicines. The Company
combines approved and development medications with its proprietary
and innovative drug delivery technologies, to provide compelling
products that have the potential to powerfully impact the
lives of patients.
The Company has developed three in-house technology platforms,
each with its own unique mechanism to improve delivery of
medications to sites of disease. All of the Company's technologies
have successfully entered human use in the clinic, providing
important validation of the potential for each platform:
* Q-Sphera(TM) platform: a disruptive micro-technology
used for sustained release to prolong and control the
release of therapeutics over an extended period of
time (from weeks to months).
* MidaSolve(TM) platform: an innovative nanotechnology
used to dissolve insoluble drugs so that they can be
administered in liquid form directly and locally into
tumours.
* MidaCore(TM) platform: a leading-edge nanotechnology
used for targeting medications to sites of disease.
The platform nature of the technologies offers the potential
to develop multiple drug assets rather than being reliant
on a limited number of programmes. Midatech's technologies
are supported by 36 patent families including 120 granted
patents and an additional 70 patent applications. Midatech's
headquarters and R&D facility is in Cardiff, UK. For more
information please visit www.midatechpharma.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABBGDXBSDDGXR
(END) Dow Jones Newswires
March 27, 2023 07:46 ET (11:46 GMT)
Midatech Pharma (LSE:MTPH)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Midatech Pharma (LSE:MTPH)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
